Abstract:Persistent SARS-CoV-2 infections are a likely source of new variants of concern. In a fatal infection in an immunocompromised patient, we find association between viral load and diversity, and abrupt diversification between contemporaneous nasopharyngeal and endotracheal aspirate samples following remdesivir and convalescent plasma treatment. Shared high proportion of G>T mutations suggests spread of viruses from the lower to the upper tract as the patient deteriorated. We identified the S:P812S spike mutation adjacent to the fusion peptide unique to the nasopharyngeal sample site. We find P812S reduced S1/S2 cleavage and decreased entry efficiency in cell lines with a range of ACE2 and TMPRSS2 expression levels. This reduction of infectivity contrasted with reduced susceptibility to neutralising antibodies in sera from vaccinated individuals conferred by P812S at both 37°C and 32°C (simulating upper tract). Thus, S:P812S is a specific adaptation during SARS-CoV-2 intrahost evolution, allowing immune evasion at lower temperatures observed in the upper respiratory tract at the expense of target cell entry efficiency.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how SARS - CoV - 2 adapts and generates new variants during chronic infection in immunocompromised patients. Specifically, the study focused on the emergence of the P812S mutation and its impact on viral characteristics. The P812S mutation is located near the spike protein fusion peptide. The study found that this mutation may be related to the specific selection of the virus in the upper respiratory tract, and a significant increase in this mutation was observed in nasopharyngeal samples after treatment with remdesivir and convalescent plasma. In addition, the study also explored the effects of the P812S mutation on the efficiency of virus entry into cells, the S1/S2 cleavage efficiency, and the sensitivity to neutralizing antibodies. ### Summary of main problems: 1. **Emergence of the P812S mutation**: The study found that the P812S mutation emerged in immunocompromised patients with chronic infection, especially in nasopharyngeal samples. 2. **Viral adaptability**: To explore whether the P812S mutation is an adaptive change of the virus in the upper respiratory tract and the impact of this change on viral characteristics. 3. **Treatment response**: To study the changes of the P812S mutation after treatment with remdesivir and convalescent plasma, and the impact of these treatments on viral diversity and load. 4. **Immune escape**: To analyze whether the P812S mutation endows the virus with the ability to escape vaccine - induced neutralizing antibodies, especially its performance under different temperature conditions. ### Research methods: - **Sample collection and sequencing**: Extract viral DNA from patients' upper respiratory tract (nasopharyngeal swabs) and lower respiratory tract (tracheal aspirates) samples and perform high - throughput sequencing. - **Genetic diversity analysis**: Use Shannon entropy to calculate the genetic diversity of each sample. - **Virus entry and cleavage efficiency**: Evaluate the effects of the P812S mutation on virus entry into cells and S1/S2 cleavage efficiency through cell experiments. - **Neutralizing antibody sensitivity**: Use the pseudovirus system to test the sensitivity of the P812S mutation to serum neutralizing antibodies from different sources. ### Key findings: - **Specificity of the P812S mutation**: The P812S mutation mainly appears in nasopharyngeal samples, suggesting its specific selection in the upper respiratory tract. - **Reduced virus entry efficiency**: The P812S mutation reduces the efficiency of virus entry into cells, especially in cell lines with different ACE2 and TMPRSS2 expression levels. - **Immune escape**: The P812S mutation increases the virus's sensitivity to vaccine - induced neutralizing antibodies, but this effect varies in different viral backgrounds. - **Temperature - dependence**: The P812S mutation shows stronger immune escape ability at lower temperatures (simulating the upper respiratory tract environment). ### Conclusion: The P812S mutation is an adaptive change that occurs during chronic infection in immunocompromised patients. It has a specific selection advantage in the upper respiratory tract, although this change comes at the cost of sacrificing the efficiency of virus entry into cells. This finding helps to understand the evolutionary mechanisms of SARS - CoV - 2 in different hosts and environments and provides an important reference for future virus monitoring and vaccine design.

Nasopharyngeal specific selection and emergence of SARS-CoV-2 spike fusion peptide mutation P812S during chronic infection

The significance of recurrent de novo amino acid substitutions that emerged during chronic SARS-CoV-2 infection: an observational study

Intrahost evolution leading to distinct lineages in the upper and lower respiratory tracts during SARS-CoV-2 prolonged infection

SARS-CoV-2 evolution during treatment of chronic infection

V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity

N439K Variant in Spike Protein Alter the Infection Efficiency and Antigenicity of SARS-CoV-2 Based on Molecular Dynamics Simulation

Adaptive Evolution of the Spike Protein in Coronaviruses

Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies

The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2

Intra-Host Evolution Analyses in an Immunosuppressed Patient Supports SARS-CoV-2 Viral Reservoir Hypothesis

SARS-CoV-2 NSP12 associates with TRiC and the P323L substitution acts as a host adaption

Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages

Spike substitution T813S increases Sarbecovirus fusogenicity by enhancing the usage of TMPRSS2

Emerging mutations in spike and other structural proteins of SARS-CoV-2

Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion

A substitution at the cytoplasmic tail of the spike protein enhances SARS-CoV-2 infectivity and immunogenicity

SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity

Intra-host evolution during SARS-CoV-2 prolonged infection

High-throughput screening of spike variants uncovers the key residues that alter the affinity and antigenicity of SARS-CoV-2

SARS-CoV-2 evolution during prolonged infection in immunocompromised patients

SARS-CoV-2 Omicron variations reveal mechanisms controlling cell entry dynamics and antibody neutralization